Processa Pharma Analyst Ratings
Processa Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/12/2023 | 313.22% | Maxim Group | $9 → $5 | Maintains | Buy |
| 04/19/2022 | 643.8% | Maxim Group | → $9 | Initiates Coverage On | → Buy |
| 08/03/2021 | 1552.89% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 1552.89% | Oppenheimer | → $20 | Initiates Coverage On | → Outperform |
| 10/28/2020 | 891.74% | Craig-Hallum | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月12日 | 313.22% | Maxim集團 | $9→$5 | 維護 | 買 |
| 04/19/2022 | 643.8% | Maxim集團 | →$9 | 開始承保 | →購買 |
| 08/03/2021 | 1552.89% | 奧本海默 | →$20 | 開始承保 | →跑贏大盤 |
| 08/02/2021 | 1552.89% | 奧本海默 | →$20 | 開始承保 | →跑贏大盤 |
| 10/28/2020 | 891.74% | 克雷格-哈勒姆 | →$12 | 開始承保 | →購買 |
What is the target price for Processa Pharma (PCSA)?
Processa Pharma(PCSA)的目標價是多少？
The latest price target for Processa Pharma (NASDAQ: PCSA) was reported by Maxim Group on January 12, 2023. The analyst firm set a price target for $5.00 expecting PCSA to rise to within 12 months (a possible 313.22% upside). 2 analyst firms have reported ratings in the last year.
梅克西姆集團於2023年1月12日報道了Processa Pharma(納斯達克：PCSA)的最新目標價。這家分析公司將目標價定為5美元，預計PCSA將在12個月內上漲至(可能上漲313.22%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Processa Pharma (PCSA)?
Processa Pharma(PCSA)的最新分析師評級是多少？
The latest analyst rating for Processa Pharma (NASDAQ: PCSA) was provided by Maxim Group, and Processa Pharma maintained their buy rating.
梅克西姆集團提供了對Processa Pharma(納斯達克代碼：PCSA)的最新分析師評級，Processa Pharma維持其買入評級。
When is the next analyst rating going to be posted or updated for Processa Pharma (PCSA)?
Processa Pharma(PCSA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on January 12, 2023 so you should expect the next rating to be made available sometime around January 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Processa Pharma的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Processa Pharma的上一次評級是在2023年1月12日提交的，因此您應該預計下一次評級將在2024年1月12日左右提供。
Is the Analyst Rating Processa Pharma (PCSA) correct?
分析師評級Processa Pharma(PCSA)正確嗎？
While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a maintained with a price target of $9.00 to $5.00. The current price Processa Pharma (PCSA) is trading at is $1.21, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Processa Pharma(PCSA)評級保持不變，目標價在9.00美元至5.00美元之間。Processa Pharma(PCSA)目前的交易價格為1.21美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。